Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2 : Synthesis, kinase inhibition and co-crystal structure
Copyright © 2021 Elsevier Masson SAS. All rights reserved..
Pharmacological inhibition of cyclin-dependent kinases has emerged as a possible treatment option for various cancer types. We recently identified substituted imidazo[1,2-c]pyrimidin-5(6H)-ones as inhibitors of cyclin-dependent kinase 2 (CDK2). Here, we report the synthesis of derivatives modified at positions 2, 3, 6 or 8 prepared using Suzuki-Miyaura cross-coupling, halogenation, Dimroth-type rearrangement and alkylation as the main synthetic methods. The compounds displayed micro- to submicromolar inhibition of CDK2/cyclin E activity. Binding of the most potent compound 3b to CDK2 was determined using isothermal titration calorimetry. The co-crystal structure of 3b in complex with fully active CDK2 was solved, revealing the binding mode of 3b in the ATP pocket and a hydrogen bonding interaction with hinge region residue Leu83. Evaluation against leukaemia cell lines revealed low cytotoxicity, which is in line with the high selectivity towards CDK2. This study demonstrates that substituted imidazo[1,2-c]pyrimidines can be exploited for future kinase inhibitor development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:216 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 216(2021) vom: 15. Apr., Seite 113309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jansa, Josef [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.04.2021 Date Revised 22.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2021.113309 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322686172 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322686172 | ||
| 003 | DE-627 | ||
| 005 | 20231225182550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2021.113309 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1075.xml |
| 035 | |a (DE-627)NLM322686172 | ||
| 035 | |a (NLM)33711765 | ||
| 035 | |a (PII)S0223-5234(21)00158-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jansa, Josef |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2 |b Synthesis, kinase inhibition and co-crystal structure |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2021 | ||
| 500 | |a Date Revised 22.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Pharmacological inhibition of cyclin-dependent kinases has emerged as a possible treatment option for various cancer types. We recently identified substituted imidazo[1,2-c]pyrimidin-5(6H)-ones as inhibitors of cyclin-dependent kinase 2 (CDK2). Here, we report the synthesis of derivatives modified at positions 2, 3, 6 or 8 prepared using Suzuki-Miyaura cross-coupling, halogenation, Dimroth-type rearrangement and alkylation as the main synthetic methods. The compounds displayed micro- to submicromolar inhibition of CDK2/cyclin E activity. Binding of the most potent compound 3b to CDK2 was determined using isothermal titration calorimetry. The co-crystal structure of 3b in complex with fully active CDK2 was solved, revealing the binding mode of 3b in the ATP pocket and a hydrogen bonding interaction with hinge region residue Leu83. Evaluation against leukaemia cell lines revealed low cytotoxicity, which is in line with the high selectivity towards CDK2. This study demonstrates that substituted imidazo[1,2-c]pyrimidines can be exploited for future kinase inhibitor development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Activity assay | |
| 650 | 4 | |a Co-crystal | |
| 650 | 4 | |a Cyclin-dependent kinase 2 | |
| 650 | 4 | |a ITC | |
| 650 | 4 | |a Kinase inhibitor | |
| 650 | 4 | |a X-ray crystallography | |
| 650 | 4 | |a imidazo[1,2-c]pyrimidin-5(6H)-one | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a imidazo(1,2-c)pyrimidine |2 NLM | |
| 650 | 7 | |a CDK2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 700 | 1 | |a Jorda, Radek |e verfasserin |4 aut | |
| 700 | 1 | |a Škerlová, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Pachl, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Peřina, Miroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Řezníčková, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Heger, Tomáš |e verfasserin |4 aut | |
| 700 | 1 | |a Gucký, Tomáš |e verfasserin |4 aut | |
| 700 | 1 | |a Řezáčová, Pavlína |e verfasserin |4 aut | |
| 700 | 1 | |a Lyčka, Antonín |e verfasserin |4 aut | |
| 700 | 1 | |a Kryštof, Vladimír |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 216(2021) vom: 15. Apr., Seite 113309 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:216 |g year:2021 |g day:15 |g month:04 |g pages:113309 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2021.113309 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 216 |j 2021 |b 15 |c 04 |h 113309 | ||